''
The award citation points to Professor Brimble’s discovery of Trofinetide (NNZ2566), a new drug for neurodevelopmental disorders, as an example of her work in this field. Trofinetide will be used to treat Rett Syndrome, a rare disorder affecting females and Fragile X Syndrome, an inherited cause of intellectual disability among boys.
Trofinetide is now being fast tracked into the marketplace by the US Food and Drug Administration; an extremely rare occurrence for medicinal drugs developed in university laboratories. Trofinetide is expected to be available in 2017.''
Given this statement,how the hell are we at this current sp,regardless of a pending CR?
'' The award citation points to Professor Brimble’s discovery of...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
-0.830(5.31%) |
Mkt cap ! $1.924B | |||
| Open | High | Low | Value | Volume |
| $15.65 | $15.72 | $14.76 | $11.61M | 772.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 9544 | $14.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.84 | 734 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |